Vienna, Austria’s Hookipa Biotech is taking a cytomegalovirus vaccine candidate into first-in-human trials. Dubbed HB-101, the vaccine will undergo Phase I…

An HIV vaccine research team led by Texas Biomedical Research Institute has secured $23 million in NIH grant funding to explore an approach that will utilize…

On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.

Pfizer’s blockbuster vaccine Prevenar 13 will soon get a boost in a host of international markets. The shot won WHO backing in a new, easier-to-store…

Just as efforts to develop a vaccine against Zika intensified this month, Congress left on vacation without passing a Zika funding bill, potentially delaying…

With HPV rates on the rise in the U.K., researchers are pushing health authorities to include boys in an HPV vaccination program currently offered to females…

Already the world’s best-selling vaccine, Pfizer’s Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49.

Even as some of the world’s largest drugmakers ante up in the Zika vaccine hunt, some smaller biotechs are looking to play their part in the search for a…

After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National…